Patients With Alzheimer S Articles & Analysis
19 news found
Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that management will be presenting at the upcoming conferences: BioFuture Panel Title: New Diagnostics: Revolutionizing Care in Alzheimer’s Date/Time: Wednesday, Nov. 9, ...
Oxford Brain Diagnostics, a software company focused on developing diagnostics that identify changes in the brain at a cellular level, today announced that their Cortical Disarray Measurement (CDM®) has been appointed as a secondary outcome measure for a Randomized, PlaceboControlled, Double-Blind Study of XPro™ in Patients with Mild ...
“We are extremely pleased to receive this R44 grant which will allow us to plan for a Phase 1b, doubleblind clinical study of OLX-07010 in patients with Alzheimer’s disease,” said William Erhardt, M.D., President and Head of Development at Oligomerix. “The proposed work is designed to support longerterm dosing required to ...
Beacon Biosignals, a startup that applies AI to EEG to unlock precision medicine for neurological and psychiatric disorders, presented research at the Alzheimer's Association International Conference, which took place July 31–Aug. 4, 2022, in San Diego. Medical Director Jay Pathmanathan, MD, PhD, discussed how the company has applied its machine learning platform to standard ...
Mission Based Media, a leader in podcasts about health, care and well-being, has launched a new podcast miniseries about Alzheimer's disease. The Alzheimer's Podcast miniseries provides insights and information for those who are diagnosed with Alzheimer's disease and the people who care about them. The miniseries was created with support from Altoida, a leading platform to improve drug ...
” Kurve has had success in improving the lives of Alzheimer’s patients through five double-blind, placebo-controlled Phase II studies. Kurve’s devices demonstrated significant success in administering intranasal insulin for Alzheimer’s disease in an 18-month Phase II ...
Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease. “We are excited that the FDA has granted UB-311 Fast Track Designation, as it recognizes the evidence demonstrating the potential for UB-311 to address a serious unmet medical need for patients with Alzheimer’s ...
ByVaxxinit
Beacon Biosignals, which applies AI to EEG to unlock precision medicine for brain conditions, today announced a partnership with Stratus, the nation's leading provider of EEG services, to enable expanded clinical trial service capabilities by leveraging Beacon's machine learning neuroanalytics platform. EEG is standard of care in the clinical diagnosis and management of many neurologic diseases ...
(Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the first patient has been dosed in the Phase 3 TRANQUILITY II study of BXCL501, the Company’s proprietary, orally dissolving thin film formulation of ...
(NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) for the addition of a Miami VA clinical site to its ongoing Phase 2 ...
(NASDAQ: LGVN), a clinical-stage biopharma company developing cellular therapies for aging-related illnesses, chronic disorders, and other specific life-threatening conditions, announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer’s disease (AD) in ...
Phase 2 TRAILBLAZER-ALZ results presented today by Eli Lilly and Company (NYSE: LLY) at the 15th International Conference on Alzheimer's & Parkinson Diseases™ 2021 (AD/PD™ 2021) held virtually March 9-14, 2021 and published simultaneously in the New England Journal of Medicine (NEJM) expand on previously reported top-line data that found donanemab met its primary endpoint and ...
The next step is to assess the blood test in a larger pool of early Alzheimer’s patients to validate it for widespread use. The Foundation for the National Institutes of Health’s Biomarkers Consortium project Plasma Abeta as a Predictor of Amyloid Positivity in Alzheimer’s ...
Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced an oral presentation of data from its phase 2a study ALK6019-201 in mild-to-moderate Alzheimer’s Disease at the 12th Clinical Trials on Alzheimer’s Disease ...
Optos Plc, a subsidiary of Nikon Corporation, Japan, and Amydis, Inc. today announced a clinical alliance focused on the development of an eye test by Amydis to detect Alzheimer’s disease. Amydis has developed a pipeline of compounds to detect amyloid proteins in the retina to be visualized with Optos’ market-leading optomap ultra-widefield retinal ...
“To me, that’s a hollow acceptance,” Peterson said. “I think we can do much ...
New findings in mice suggest that the timing when the neurotransmitter acetylcholine is released in the brain's hippocampus may play a key role in regulating the strength of nerve cell connections, called synapses. Understanding the complex nature of neuronal signaling at synapses could lead to better understanding of learning and memory, and novel treatments for relevant disorders, such as ...
New findings in mice suggest that the timing when the neurotransmitter acetylcholine is released in the brain's hippocampus may play a key role in regulating the strength of nerve cell connections, called synapses. Understanding the complex nature of neuronal signaling at synapses could lead to better understanding of learning and memory, and novel treatments for relevant disorders, such as ...
The collaborative study, initiated by PerkinElmer and David Bennett, M.D., Director of the Rush Alzheimer's Disease Center, Rush University Medical Center ( Chicago , Illinois ), is among the first study of its kind to describe a potential diagnostic blood test for Alzheimer's disease, although the results will need replication in a separate study. ...